Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azenta, Inc.'s SEC filings document operating results, material events, governance matters and acquisition agreements for a life sciences solutions company built around cold-chain sample management and multiomics services. Recent Form 8-K disclosures include quarterly results and financial-condition updates, leadership and board changes, and the material definitive agreement under which Azenta UK Ltd acquired UK Biocentre.
The company’s proxy and annual-meeting filings describe director elections, advisory executive-compensation votes, equity incentive plan amendments and auditor ratification. Together with material-event reports, these filings provide formal disclosure on Azenta’s governance structure, capital-related authorizations, transaction terms and recurring public-company reporting obligations.
Azenta, Inc. (AZTA) reported an amended Form 4 for its President and CEO, who is also a Director. The amendment corrects the transaction code to "P" for a purchase of 1,000 common shares at $25.99 on 06/02/2025. Following the transaction, the reporting person beneficially owned 107,295.78 shares, held directly.
The amendment also adds a Power of Attorney authorizing filings of Forms 3, 4, and 5 on the reporting person’s behalf.
Azenta, Inc. (AZTA) reported an amended Form 4 for a director reflecting a common stock purchase and administrative corrections. The filing shows the director acquired 12,000 common shares on 05/30/2025 at $26.65 per share. Following the transaction, the director beneficially owned 17,035 shares, held directly.
The amendment adds the Power of Attorney that was omitted from the original and corrects the transaction code previously reported as “A” to the correct code “P.”
Azenta, Inc. (AZTA) filed an amended Form 4 reporting an insider transaction by SVP and GM, Multiomics, Ginger Zhou. On 08/12/2025, a sale (transaction code S) of 1,085 shares of common stock was reported at a price of $28.54 per share.
Following the transaction, the reporting person beneficially owned 26,831 shares, held directly. The amendment also notes two administrative corrections: inclusion of a Power of Attorney that was omitted from the original filing on 08/13/2025, and correction of the transaction code from “D” to the correct code “S.”
Azenta insider sale tied to RSU vesting. Ginger Zhou, SVP and GM, Multiomics, disposed of 1,085 common shares on 08/12/2025 to satisfy withholding tax obligations arising from the vesting of 3,167 restricted stock units that vested on 08/09/2025. The reported sale price was $28.54 per share.
After the transaction the reporting person beneficially owned 26,831 shares. The Form 4 discloses this as a routine tax-withholding disposition rather than an open-market trading decision.
Azenta insider Olga Pirogova, who serves as SVP and CHRO, reported a disposition of common stock related to tax withholding on vested restricted stock units. The filing shows a sale of 1,085 shares at a reported price of $28.54 executed on 08/12/2025 to satisfy tax withholding obligations arising from the vesting on 08/09/2025 of 3,167 restricted stock units. After the transaction the reporting person beneficially owns 18,288 shares.
This is a routine, compensation-related sale rather than an unsolicited market disposition: the explanatory note explicitly states the sale was to meet withholding tax obligations on vested RSUs. No derivative transactions were reported in the filing.
Lawrence Y. Lin, Azenta's EVP, Chief Financial Officer and Treasurer, reported an open-market purchase of 2,500 common shares on 08/11/2025 at a price of $27.96 per share. After the transaction, his beneficial ownership increased to 46,013 shares.
The filing is a routine Form 4 disclosure showing an insider purchase executed in the open market. The report does not include any derivative transactions or indications of a planned trading program; the explanation provided states simply: "Open market purchase."
Azenta, Inc. filed a Current Report on Form 8-K dated August 5, 2025 announcing via press release its financial results for the fiscal quarter ended June 30, 2025.
The press release is attached as Exhibit 99.1 and the Cover Page Interactive Data File is included as Exhibit 104. The filing states the Item 2.02 disclosure and Exhibit 99.1 are not deemed "filed" under Section 18 of the Exchange Act and contains a cautionary note regarding forward-looking statements. The report was signed by Ephraim Starr, Senior Vice President, General Counsel and Secretary, dated August 5, 2025. This Form 8-K does not include any numerical financial metrics; readers should consult Exhibit 99.1 for the detailed results.